Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hypertension Diagnostics Inc (HDII) -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (61)	3/2/2001 2:04:26 PM
From: scott_jiminez	Read Replies (1) \| Respond to of 120

Another billion+ perspective Profilor patients HDII in China! To quote HHH, I'm 'pleased as punch'. (note also the new patent in Hong Kong - my bolding) ---------------- Friday March 2, 1:11 pm Eastern Time Press Release SOURCE: Hypertension Diagnostics, Inc. Hypertension Diagnostics Introduces HDI/PulseWave(TM Technology in China ST. PAUL, Minn., March 2 /PRNewswire/ -- Hypertension Diagnostics, Inc. (Nasdaq SmallCap: HDII; HDIIW; HDIIU), today announced that it sold ten of its HDI/PulseWave(TM) CR-2000 Research CardioVascular Profiling Systems to China in support of a ten-site research study designed to obtain arterial elasticity values from a diverse geographic group of approximately 2,000 healthy individuals. The study, ``A Multi-Site Study of a Healthy Chinese Population to Establish Reference Ranges for Hemodynamic Parameters Obtained Non-Invasively Using the HDI CardioVascular Profiling System,'' is being conducted under the financial backing of HDI's exclusive Chinese distributor, Shenzhen Zhongshen Medical Apparatus & Instruments Co., Ltd. and under the medical direction of their Principal Investigator, Professor Weizhong Zhang, M.D., of the Shanghai Institute of Hypertension in Shanghai, China. Each of the ten sites will be collecting arterial elasticity data from normal, healthy male and female subjects between the ages of 15 and 80 years of age. The results of this study will provide Chinese physicians with the first-ever comparative clinical data that will be clinically beneficial to them for screening, diagnosing and monitoring the treatment of patients with cardiovascular disease. Extensive scientific research has shown that a premature loss of blood vessel elasticity is associated with cardiovascular disease and an increase in morbid cardiovascular events. A ``normal'' reference range for elasticity values adjusted by age, height, weight and gender will allow physicians to better identify those patients who are at the highest risk for developing cardiovascular disease. HDI has been advised that Shenzhen Zhongshen Medical Apparatus & Instruments Co., Ltd. has an annual revenue of approximately $18 million (U.S. equivalent), has more than 100 employees in ten branch offices throughout China, two branch offices in Houston, Texas and Gardena, Calif., and is headquartered in Shenzhen, China. The firm's president, Mr. Fuquan Liu, has elected to conduct this large nationwide arterial elasticity study to obtain information that will be used to develop the CVProfilor(TM) MD-3000 System physician practice model to be marketed throughout China and as a way to demonstrate the importance of the technology to key hypertension opinion leaders throughout China. ``China is the most populous nation in the world with over 1.2 billion people,'' said Greg H. Guettler, President. ``There are 50-60 million patients with hypertension in China and cardiovascular disease claims approximately 2.5 million lives annually. This multi-site study is a significant step in our worldwide launch of HDI's pulse wave analysis technology. We believe that this market provides HDI with an exciting opportunity to make world history as the first company to collect small artery elasticity data in China and to significantly grow our business internationally,'' said Guettler. Shenzhen Zhongshen Medical Apparatus & Instruments Co., Ltd. has exclusive distribution rights to HDI's products in all Chinese provinces, including Hong Kong. Following completion of this study, formal regulatory approval for the marketing of the CVProfilor(TM) MD-3000 System will need to be obtained through the government of the Peoples Republic of China. HDI has received notification that a Certificate of Grant of Patent has been awarded by the Patents Registry in Hong Kong. Patent No. HK1014351, entitled ``Vascular Impedance Measurement Instrument'', was applied for during 1991 and has a term expiring in 2011. This Hong Kong patent excludes others from making, marketing, using, importing or stocking a product similar to HDI's CardioVascular Profiling System without authorization from HDI. The issuance of this patent expands HDI's intellectual property portfolio to twelve patents including one each for Europe and Japan, as well as several pending patent applications. (abridged) -------------------- biz.yahoo.com